{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T02:43:23Z","timestamp":1792205003418,"version":"4.4.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.ejpb.2020.08.014","type":"journal-article","created":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T20:19:06Z","timestamp":1598732346000},"page":"11-19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Safe, swallowable and palatable paediatric mini-tablet formulations for a WHO model list of essential medicines for children compound \u2013 A promising starting point for future PUMA applications"],"prefix":"10.1016","volume":"156","author":[{"given":"Lisa","family":"Freerks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Sommerfeldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia C.","family":"L\u00f6per","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2020.08.014_b0005","unstructured":"Regulation (EC) No 1901\/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768\/92, Directive 2001\/20\/EC, Directive 2001\/83\/EC and Regulation (EC) No 726\/2004: Paediatric Regulation; 2006. Available from: URL: https:\/\/ec.europa.eu\/health\/\/sites\/health\/files\/files\/eudralex\/vol-1\/reg_2006_1901\/reg_2006_1901_en.pdf."},{"key":"10.1016\/j.ejpb.2020.08.014_b0010","unstructured":"State of Paediatric Medicines in the EU 10 years of the EU Paediatric Regulation: Report from the Commission to the European Parliament and the Council; COM (2017) 626; 2017. Available from: URL: https:\/\/ec.europa.eu\/health\/sites\/health\/files\/files\/paediatrics\/docs\/2017_childrensmedicines_report_en.pdf."},{"issue":"2","key":"10.1016\/j.ejpb.2020.08.014_b0015","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1208\/s12249-016-0558-3","article-title":"Paediatric drug development and formulation design-a European perspective","volume":"18","author":"van Riet-Nales","year":"2017","journal-title":"AAPS PharmSciTech"},{"issue":"3","key":"10.1016\/j.ejpb.2020.08.014_b0020","first-page":"122","article-title":"Physicochemical characterisation of fluids and soft foods frequently mixed with oral drug formulations prior to administration to children","volume":"71","author":"Kersten","year":"2016","journal-title":"Pharmazie"},{"issue":"5","key":"10.1016\/j.ejpb.2020.08.014_b0025","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.phrs.2011.01.006","article-title":"Paediatric pharmacology: remember the excipients","volume":"63","author":"Fabiano","year":"2011","journal-title":"Pharmacol. Res."},{"issue":"2","key":"10.1016\/j.ejpb.2020.08.014_b0030","article-title":"Safe excipient exposure in neonates and small children - protocol for the SEEN project","volume":"64","author":"Valeur","year":"2017","journal-title":"Dan. Med. J."},{"issue":"4","key":"10.1016\/j.ejpb.2020.08.014_b0035","first-page":"251","article-title":"Excipients in neonatal medicinal products: never prescribed, commonly administered","volume":"32","author":"Valeur","year":"2018","journal-title":"Pharmaceut. Med."},{"issue":"7","key":"10.1016\/j.ejpb.2020.08.014_b0040","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1136\/archdischild-2015-308227","article-title":"Safe and effective pharmacotherapy in infants and preschool children: importance of formulation aspects","volume":"101","author":"van Riet-Nales","year":"2016","journal-title":"Arch. Dis. Child."},{"issue":"5","key":"10.1016\/j.ejpb.2020.08.014_b0045","first-page":"14","article-title":"Pharmaceutical excipients and pediatric formulations","volume":"30","author":"Yochana","year":"2012","journal-title":"Chem. Today (Chimica Oggi)"},{"issue":"2","key":"10.1016\/j.ejpb.2020.08.014_b0050","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.ijpharm.2017.07.042","article-title":"Challenges and strategies to facilitate formulation development of pediatric drug products: Safety qualification of excipients","volume":"536","author":"Buckley","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2020.08.014_b0055","unstructured":"STEPdatabase [cited 2019 Oct 08]. Available from: URL: https:\/\/step-db.ucl.ac.uk\/eupfi\/appDirectLink.do?appFlag=login."},{"issue":"2","key":"10.1016\/j.ejpb.2020.08.014_b0060","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ijpharm.2012.05.004","article-title":"The STEP (safety and toxicity of excipients for paediatrics) database. Part 1-A need assessment study","volume":"435","author":"Salunke","year":"2012","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.ejpb.2020.08.014_b0065","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ijpharm.2013.09.013","article-title":"The STEP (safety and toxicity of excipients for paediatrics) database: part 2 - the pilot version","volume":"457","author":"Salunke","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2020.08.014_b0070","unstructured":"World Health Organization Model List of Essential Medicines List for Children: 7th List; 2019 [cited 2019 Oct 08]. Available from: URL: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/325772\/WHO-MVP-EMP-IAU-2019.07-eng.pdf?ua=1."},{"key":"10.1016\/j.ejpb.2020.08.014_b0075","unstructured":"Inventory of the needs for paediatric medicines [cited 2019 Oct 08]. Available from: URL: https:\/\/www.ema.europa.eu\/en\/human-regulatory\/research-development\/paediatric-medicines\/needs-paediatric-medicines#."},{"key":"10.1016\/j.ejpb.2020.08.014_b0080","unstructured":"Reflection paper: Formulations of Choice for the Paediatric Population. London; 2006 EMEA\/CHMP\/PEG\/194810\/2005. Available from: URL: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/reflection-paper-formulations-choice-paediatric-population_en.pdf."},{"issue":"4","key":"10.1016\/j.ejpb.2020.08.014_b0085","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/jphp.12610","article-title":"Evidence of acceptability of oral paediatric medicines: a review","volume":"69","author":"Mistry","year":"2017","journal-title":"J. Pharm. Pharmacol."},{"issue":"1\u20132","key":"10.1016\/j.ejpb.2020.08.014_b0090","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ijpharm.2015.05.013","article-title":"Formulation factors affecting acceptability of oral medicines in children","volume":"492","author":"Liu","year":"2015","journal-title":"Int. J. Pharm."},{"issue":"2","key":"10.1016\/j.ejpb.2020.08.014_b0095","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ijpharm.2017.07.017","article-title":"Patient acceptability, safety and access: A balancing act for selecting age-appropriate oral dosage forms for paediatric and geriatric populations","volume":"536","author":"Walsh","year":"2018","journal-title":"Int. J. Pharm."},{"issue":"3","key":"10.1016\/j.ejpb.2020.08.014_b0100","doi-asserted-by":"crossref","first-page":"238","DOI":"10.2471\/BLT.16.171967","article-title":"Medicines for children: flexible solid oral formulations","volume":"95","author":"Orubu","year":"2017","journal-title":"Bull. World Health Organ."},{"issue":"15","key":"10.1016\/j.ejpb.2020.08.014_b0105","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.3109\/03639049409042643","article-title":"A comparison of the dissolution characteristics of theophylline from film coated granules and mini-tablets","volume":"20","author":"Munday","year":"1994","journal-title":"Drug Dev. Ind. Pharm."},{"issue":"1","key":"10.1016\/j.ejpb.2020.08.014_b0110","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0378-5173(98)00206-3","article-title":"Minitabletting: improving the compactability of paracetamol powder mixtures","volume":"173","author":"Lennartz","year":"1998","journal-title":"Int. J. Pharm."},{"issue":"2","key":"10.1016\/j.ejpb.2020.08.014_b0115","doi-asserted-by":"crossref","first-page":"e235","DOI":"10.1542\/peds.2008-2059","article-title":"Minitablets: new modality to deliver medicines to preschool-aged children","volume":"123","author":"Thomson","year":"2009","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.ejpb.2020.08.014_b0120","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.ejpb.2011.02.005","article-title":"Orally disintegrating mini-tablets (ODMTs)\u2013a novel solid oral dosage form for paediatric use","volume":"78","author":"Stoltenberg","year":"2011","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"9","key":"10.1016\/j.ejpb.2020.08.014_b0125","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1136\/archdischild-2012-303303","article-title":"Acceptability of different oral formulations in infants and preschool children","volume":"98","author":"van Riet-Nales","year":"2013","journal-title":"Arch. Dis. Child."},{"issue":"1","key":"10.1016\/j.ejpb.2020.08.014_b0130","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1517\/17425247.2014.951633","article-title":"Mini-tablets: a contemporary system for oral drug delivery in targeted patient groups","volume":"12","author":"Aleksovski","year":"2015","journal-title":"Expert Opin. Drug Deliv."},{"issue":"202\u2013207","key":"10.1016\/j.ejpb.2020.08.014_b0135","article-title":"Acceptability of multiple uncoated minitablets in infants and toddlers: a randomized controlled trial","volume":"201","author":"Klingmann","year":"2018","journal-title":"J. Pediatr."},{"issue":"Suppl 10","key":"10.1016\/j.ejpb.2020.08.014_b0140","first-page":"S26","article-title":"Drug formulations: standards and novel strategies for drug administration in pediatrics","volume":"58","author":"Thabet","year":"2018","journal-title":"J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.ejpb.2020.08.014_b0145","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.jpeds.2015.07.010","article-title":"Acceptability of uncoated mini-tablets in neonates\u2014a randomized controlled trial","volume":"167","author":"Klingmann","year":"2015","journal-title":"J. Pediatr."},{"issue":"2","key":"10.1016\/j.ejpb.2020.08.014_b0150","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1208\/s12249-016-0639-3","article-title":"Acceptability of mini-tablets in young children: results from three prospective cross-over studies","volume":"18","author":"Klingmann","year":"2017","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejpb.2020.08.014_b0155","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.addr.2013.10.006","article-title":"Paediatric oral biopharmaceutics: key considerations and current challenges","volume":"73","author":"Batchelor","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"10.1016\/j.ejpb.2020.08.014_b0160","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.ijpharm.2017.08.088","article-title":"Assessment of swallowability and palatability of oral dosage forms in children: Report from an M-CERSI pediatric formulation workshop","volume":"536","author":"Ternik","year":"2018","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.ejpb.2020.08.014_b0165","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1517\/17425247.4.1.37","article-title":"Paediatric and geriatric drug delivery","volume":"4","author":"Breitkreutz","year":"2007","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2020.08.014_b0170","series-title":"Polyvinylpyrrolidone Excipients for Pharmaceuticals: Povidone, Crospovidone and Copovidone","author":"B\u00fchler","year":"2005"},{"issue":"Pt A","key":"10.1016\/j.ejpb.2020.08.014_b0175","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.fct.2017.05.047","article-title":"Critical review of the current literature on the safety of sucralose","volume":"106","author":"Magnuson","year":"2017","journal-title":"Food Chem. Toxicol."},{"issue":"4","key":"10.1016\/j.ejpb.2020.08.014_b0180","first-page":"141","article-title":"Solid oral dosage forms for children - Formulations, excipients and acceptance issues","volume":"7","author":"Stoltenberg","year":"2010","journal-title":"J. Appl. Therapeutic Res."},{"issue":"5","key":"10.1016\/j.ejpb.2020.08.014_b0185","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/jphp.12365","article-title":"Prediction of in-vivo pharmacokinetic profile for immediate and modified release oral dosage forms of furosemide using an in-vitro-in-silico-in-vivo approach","volume":"67","author":"Otsuka","year":"2015","journal-title":"J. Pharm. Pharmacol."},{"issue":"2","key":"10.1016\/j.ejpb.2020.08.014_b0190","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1208\/s12249-016-0671-3","article-title":"Simulating different dosing scenarios for a child-appropriate valproate ER formulation in a new pediatric two-stage dissolution model","volume":"18","author":"Karkossa","year":"2017","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejpb.2020.08.014_b0195","unstructured":"WHO Department of Nutrition for Health and Development. WHO child growth standards: Length\/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age: methods and development. Geneva: World health organization; 2006. Available from: URL: https:\/\/www.who.int\/childgrowth\/en\/."},{"issue":"10","key":"10.1016\/j.ejpb.2020.08.014_b0200","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1111\/jphp.12777","article-title":"Assessing the influence of media composition and ionic strength on drug release from commercial immediate-release and enteric-coated aspirin tablets","volume":"69","author":"Karkossa","year":"2017","journal-title":"J. Pharm. Pharmacol."},{"issue":"2","key":"10.1016\/j.ejpb.2020.08.014_b0205","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1208\/s12249-013-9933-5","article-title":"An automated system for monitoring and regulating the pH of bicarbonate buffers","volume":"14","author":"Garbacz","year":"2013","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejpb.2020.08.014_b0210","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ejps.2013.09.020","article-title":"A dynamic system for the simulation of fasting luminal pH-gradients using hydrogen carbonate buffers for dissolution testing of ionisable compounds","volume":"51","author":"Garbacz","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2020.08.014_b0215","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ejpb.2018.10.022","article-title":"Biorelevant in vitro assessment of dissolution and compatibility properties of a novel paediatric hydrocortisone drug product following exposure of the drug product to child-appropriate administration fluids","volume":"133","author":"Wollmer","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"4","key":"10.1016\/j.ejpb.2020.08.014_b0220","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00045391-200107000-00010","article-title":"Clinical pharmacology of furosemide in children: a supplement","volume":"8","author":"Prandota","year":"2001","journal-title":"Am. J. Ther."},{"issue":"4","key":"10.1016\/j.ejpb.2020.08.014_b0225","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2165\/11596620-000000000-00000","article-title":"Clinical pharmacology of the loop diuretics furosemide and bumetanide in neonates and infants","volume":"14","author":"Pacifici","year":"2012","journal-title":"Paediatr. Drugs"},{"key":"10.1016\/j.ejpb.2020.08.014_b0230","unstructured":"Generally Recognized as Safe (GRAS) Substances Database: 21 CFR 182 & 184 [cited 2019 OCt 08]. Available from: URL: https:\/\/www.fda.gov\/food\/generally-recognized-safe-gras\/gras-substances-scogs-database."},{"issue":"2","key":"10.1016\/j.ejpb.2020.08.014_b0235","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ijpharm.2010.01.038","article-title":"Novel milk-based oral formulations: proof of concept","volume":"390","author":"Charkoftaki","year":"2010","journal-title":"Int. J. Pharm."},{"issue":"1\u20132","key":"10.1016\/j.ejpb.2020.08.014_b0240","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ijpharm.2013.01.022","article-title":"Stability and physicochemical characterization of novel milk-based oral formulations","volume":"444","author":"Kytariolos","year":"2013","journal-title":"Int. J. Pharm."},{"issue":"4","key":"10.1016\/j.ejpb.2020.08.014_b0245","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/jphp.12570","article-title":"The Milky Way: paediatric milk-based dispersible tablets prepared by direct compression - a proof-of-concept study","volume":"69","author":"Orubu","year":"2017","journal-title":"J. Pharm. Pharmacol."},{"issue":"3","key":"10.1016\/j.ejpb.2020.08.014_b0250","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3109\/10837450.2013.775154","article-title":"Why is mannitol becoming more and more popular as a pharmaceutical excipient in solid dosage forms?","volume":"19","author":"Ohrem","year":"2014","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.ejpb.2020.08.014_b0255","unstructured":"Ludiflash\u00ae \u2013 The taste of success [cited 2019 July 08]. Available from: URL: https:\/\/www.btc-europe.com\/fileadmin\/user_upload\/Downloads\/Pdf_s\/Industries\/Ludiflash_Brochure_EN.pdf."},{"issue":"11","key":"10.1016\/j.ejpb.2020.08.014_b0260","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.earlhumdev.2015.08.013","article-title":"Human breast milk: A review on its composition and bioactivity","volume":"91","author":"Andreas","year":"2015","journal-title":"Early Hum. Dev."},{"issue":"3","key":"10.1016\/j.ejpb.2020.08.014_b0265","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1080\/11026480260363242","article-title":"Milk and dairy products: possible effects on dental health","volume":"46","author":"Johansson","year":"2002","journal-title":"Scand. J. Nutr."},{"key":"10.1016\/j.ejpb.2020.08.014_b0270","article-title":"Role of sugar and sugar substitutes in dental caries: a review","volume":"2013","author":"Gupta","year":"2013","journal-title":"ISRN Dent"},{"key":"#cr-split#-10.1016\/j.ejpb.2020.08.014_b0275.1","unstructured":"REGULATION (EC) No 1272\/2008 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67\/548\/EEC and 1999\/45\/EC, and amending Regulation (EC) No 1907\/2006"},{"key":"#cr-split#-10.1016\/j.ejpb.2020.08.014_b0275.2","unstructured":"2008 [cited 2019 July 04]. Available from: URL: https:\/\/eur-lex.europa.eu\/LexUriServ\/LexUriServ.do?uri=OJ:L:2008:353:0001:1355:EN:PDF."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641120302599?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641120302599?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:37:42Z","timestamp":1760546262000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641120302599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":56,"alternative-id":["S0939641120302599"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2020.08.014","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safe, swallowable and palatable paediatric mini-tablet formulations for a WHO model list of essential medicines for children compound \u2013 A promising starting point for future PUMA applications","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2020.08.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}